Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rindopepimut/GM-CSF with adjuvant temozolomide in newly diagnosed EGFRvIII-positive glioblastoma
NL-OMON39791Phase 3Active, not recruiting
- Sponsor
- Celldex Therapeutics
- Start
- Feb 2014
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in glioblastoma (GBM) comparing Rindopepimut/GM-CSF + temozolomide with KLH control + temozolomide (2 arms). Primary endpoint: Overall survival. Started Feb 2014; status: active, not recruiting.
02
Drugs
rindopepimuttemozolomidesargramostim
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NL-OMON39791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39791.